Is Pralsetinib suitable for long-term use by patients with thyroid cancer?

Pralsetinib is a selective RETkinase inhibitor, suitable for patients with thyroid cancer carrying RET gene fusion, especially when radioactive iodine treatment is ineffective or has metastasized. Its mechanism is to inhibit the growth and spread of tumor cells by precisely inhibiting the RET fusion protein signaling pathway. Studies have shown that patients with RETfusion-positive thyroid cancer have a higher objective response rate after treatment with platinib, and some patients can achieve longer disease control.

From a long-term treatment perspective, platinib has certain advantages in sustainable use. Most patients are able to maintain disease stability and achieve improvement in quality of life during treatment. Clinical trial data show that platinib is well tolerated, and most adverse reactions are controllable mild to moderate reactions, such as hypertension, elevated liver enzymes, constipation, etc., which can usually be alleviated through dose adjustment or symptomatic treatment. However, individual patients may experience serious adverse events during long-term use, such as interstitial lung disease or bone marrow suppression, and require close monitoring.

For patients who plan to take platinib for a long time, it is recommended to conduct comprehensive genetic testing before treatment to confirm the existence of RET fusion mutations to ensure the accuracy and effectiveness of treatment. At the same time, during long-term medication, blood routine, liver and kidney function and imaging examinations should be reviewed regularly to evaluate treatment response and drug safety in a timely manner. If persistent adverse reactions or decreased efficacy occur, you should discuss with your doctor whether the regimen needs to be adjusted or combined with other treatments.

In short, platinib is suitable for long-term treatment of RET patients with fusion-positive thyroid cancer, especially providing new hope for patients with poor results from traditional treatments. However, its long-term use must be carried out under the guidance of professional doctors, with regular monitoring and individualized management to balance the relationship between efficacy and safety and achieve maximum therapeutic benefits.

Reference materials:https://gavreto.com/